| Literature DB >> 24821057 |
Sergio Luiz Montego Ferreira Junior1, Elis Regina Dalla Costa1, Paula Gonçalves dos Santos2, Harrison Magdinier Gomes3, Marcia Susana Nunes Silva1, Leonardo Souza Esteves1, Martha Maria Oliveira2, Raquel de Abreu Maschmann1, Afrânio Lineu Kritski2, Philip Noel Suffys3, Maria Lucia Rosa Rossetti1.
Abstract
Drug-resistant tuberculosis (TB) threatens global TB control and is a major public health concern in several countries. We therefore developed a multiplex assay (LINE-TB/MDR) that is able to identify the most frequent mutations related to rifampicin (RMP) and isoniazid (INH) resistance. The assay is based on multiplex polymerase chain reaction, membrane hybridisation and colorimetric detection targeting of rpoB and katG genes, as well as the inhA promoter, which are all known to carry specific mutations associated with multidrug-resistant TB (MDR-TB). The assay was validated on a reference panel of 108 M. tuberculosis isolates that were characterised by the proportion method and by DNA sequencing of the targets. When comparing the performance of LINE-TB/MDR with DNA sequencing, the sensitivity, specificity and agreement were 100%, 100% and 100%, respectively, for RMP and 77.6%, 90.6% and 88.9%, respectively, for INH. Using drug sensibility testing as a reference standard, the performance of LINE-TB/MDR regarding sensitivity, specificity and agreement was 100%, 100% and 100% (95%), respectively, for RMP and 77%, 100% and 88.7% (82.2-95.1), respectively, for INH. LINE-TB/MDR was compared with GenoType MTBDRplus for 65 isolates, resulting in an agreement of 93.6% (86.7-97.5) for RIF and 87.4% (84.3-96.2) for INH. LINE-TB/MDR warrants further clinical validation and may be an affordable alternative for MDR-TB diagnosis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24821057 PMCID: PMC4131782 DOI: 10.1590/0074-0276130469
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743

A: example of the wild type (WT) result to the three genes rpoB, katG and inhA; B: example of a strain mutated in the 531 region of the rpoB gene with no hybridisation with the Rif5wt probe and hybridisation with the Rif4M; C: hybridisation with the 14 katGM probe; D: hybridisation with the probe number 11; E: hybridisation was not observed with the rif4 probe, what suggested that there are mutation in the rpoB gene codon 526, although the method have not allowed to identified the mutation; F: schematic presentation of LINE-TB/MDR. Probes position: rpoB WT probes, circles 1-5 (Rif 1, Rif 2, Rif 3, Rif 4, Rif 5); rpoB mutated probes, 6-10 (Rif1M, Rif2M, Rif3M, Rif4M, Rif5M); 11, inhAM; 12, inhAwt; 13, katGwt; 14, katGM; 15, IS6110.
Correlation between LINE-TB/MDR and sequencing
| LINE-TB/MDR pattern | LINE-TB/MDR result-location of mutation | Sequencing data | ||
|---|---|---|---|---|
| Positive probes | Gene (probe) | Nucleotide/amino acid changes | Strains n (%) | |
| 1,2,3,4* |
| S531L | TCG-TTG/Ser-Leu | 37 (69.8) |
| 1,2,3,4* |
| S531W | TCG-TGG/Ser-Trp | 1 (1.88) |
| 1,2,4,5* |
| H526D | CAC-GAC/His-Asp | 4 (7.5) |
| 1,3,4,5* |
| H526Y | CAC-TAC/His-Tyr | 4 (7.5) |
| 1,2,3,5* | Lack hybridisation | H526L | CAC-GTC/His-Leu | 1 (1.88) |
| 1,2,3,5* | Lack hybridisation at (Rif2/3M) | H526R | CAC-CGC/His-Arg | 1 (1.88) |
| 1,2,3,5* | Lack hybridisation at (Rif2/3M) | H526P | CAC-CCC/His-Pro | 1 (1.88) |
| 1,2,3,5* | Lack hybridisation at (Rif2/3M) | H526L | CAC-CTC/His-Leu | 1 (1.88) |
| 1,3,4,5* | Lack hybridisation at (Rif2/3M) | D516Y | GAC-TAC/Asp-Tyr | 2 (3.77) |
| 1,3,4,5* |
| D516V | GAC-GTC/Asp-Val | 1 (1.88) |
| 11* |
| -15 | C-T | 13 (24.6) |
| 12* |
| No mutation | WT | 40 (75.4) |
| 14* |
| S315T | AGC-ACC/Ser-Thr | 41 (77.3) |
| 13* |
| No mutation | WT | 12 (22.7) |
| 1,2,3,4,5,12,14* | WT | No mutation | WT | 55 (100) |
WT: wild type.
Comparison of the results obtained for the identification of mutation with the sequencing and with drug susceptibility testing (DST)
| Results | Compared results | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 108) | (n = 108) | |||||||||
| LINE-TB/MDR | LINE-TB/MDR | LINE-TB/MDR | LINE-TB/MDR | Kappa | SE | SP | ||||
| LINE-TB/MDR | Seq | wt/Seq wt | mut/Seq wt | wt/Seq mut | mut/Seq mut | (95% CI) | p | (%) | (%) | |
|
| ||||||||||
| INH wt | 58 | 64 | 58 | 3 | 3 | 44 | 88.9 (82.5-95.2) | < 0.001 | 77.6 | 90.6 |
| INH res | 50 | 44 | ||||||||
| RMP wt | 55 | 55 | 55 | 0 | 0 | 53 | 100 (99.5-100.0) | < 0.001 | 100 | 100 |
| RMP res | 53 | 53 | ||||||||
|
| ||||||||||
| LINE-TB/MDR | LINE-TB/MDR | LINE-TB/MDR | LINE-TB/MDR | LINE-TB/MDR | Kappa | SE | SP | |||
| DST | wt/DST-S | mut/DST-S | wt/DST-R | mut/DST-R | (95% CI) | p | (%) | (%) | ||
|
| ||||||||||
| INH wt | 55 | 55 | 55 | 0 | 12 | 41 | 88.7 (82.2-95.1) | < 0.001 | 77 | 100 |
| INH res | 41 | 53 | ||||||||
| RMP wt | 55 | 55 | 55 | 0 | 0 | 53 | 100 (99.5-100.0) | < 0.001 | 100 | 100 |
| RMP res | 53 | 53 | ||||||||
CI: confidence interval; INH: isoniazid; RMP: rifampicin; SE: sensitivities; SP: specificities.
Comparison of the results obtained for the identification of GenoType MTBDRplus with the sequencing and with LINE-TB/MDR
| Results | Compared results | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 65) | (n = 65) | |||||||||
| Hain strip | Hain strip | Hain strip | Hain strip | Hain strip | Kappa | SE | SP | |||
| Seq | wt/Seq wt | mut/Seq wt | wt/Seq mut | mut/Seq mut | (95% CI) | p | (%) | (%) | ||
|
| ||||||||||
| INH wt | 27 | 25 | 25 | 3 | 2 | 40 | 96.9 | < 0.001 | 87.0 | 100.0 |
| INH res | 38 | 40 | (89.9-98.6) | |||||||
| RMP wt | 28 | 25 | 25 | 0 | 3 | 37 | 90.5 | < 0.001 | 92.5 | 100.0 |
| RMP res | 37 | 40 | (84.3-86.4) | |||||||
| Hain strip | Hain strip | Hain strip | Hain strip | Kappa | ||||||
| Hain strip | LINE-TB/MDR | wt/LINE-TB/MDR wt | mut/LINE-TB/MDR wt | wt/LINE-TB/MDR mut | mut/LINE-TB/MDR mut | (95% CI) | p | |||
|
| ||||||||||
| INH wt | 25 | 25 | 25 | 0 | 2 | 38 | 93.6 | < 0.001 | ||
| INH res | 40 | 40 | (86.7-97.5) | |||||||
| RMP wt | 28 | 25 | 25 | 0 | 3 | 37 | 87.4 | < 0.001 | ||
| RMP res | 37 | 40 | (84.3-96.2) | |||||||
CI: confidence interval; INH: isoniazid; RMP: rifampicin; SE: sensitivities; SP: specificities.
Probe set for identification of the wild type (WT) and mutant genotypes
| Sequence | Length | Probes concentration | ||
|---|---|---|---|---|
| Probes | (5'-3') | (bp) | (pmolμL) | |
| Rif1wt | CAGCCAGCTGAGCCAATTCAT | 21 | WT | 5.0 |
| Rif2wt | TTCATGGACCAGAACAACCC | 20 | WT | 10.0 |
| Rif3wt | CGCTGTCGGGGTTGACC | 17 | WT | 10.0 |
| Rif4wt | TTGACCCACAAGCGCCGACT | 20 | WT | 5.0 |
| Rif5wt | CTGTCGGCGCTGGGGC | 16 | WT | 10.0 |
| Rif1M | CCAATTCATGGTCCAGAA | 21 | Mutant | 5.0 |
| Rif2M | GTTGACCTACAAGCGCCG | 18 | Mutant | 10.0 |
| Rif3M | GGTTGACCGACAAGCGCC | 18 | Mutant | 10.0 |
| Rif4M | CTGTTGGCGCTGGGGC | 16 | Mutant | 10.0 |
| Rif5M | CGACTGTGGGCGCTGG | 16 | Mutant | 10.0 |
|
| TCACCAGCGGCATCGAG | 17 | WT | 0.4 |
| katGM | TCACCACCGGCATCGAG | 17 | Mutant | 0.4 |
| inhAwt | CGGCGAGACGATAGGTTGTC | 20 | WT | 0.6 |
| IS6110 | TGCCCGTCCCGCCGATCTC | 18 | WT | 1.0 |
Primers used for amplification and standardisation of multiplex PCR for genes rpoB, katG, inhA and IS6110
| Size | ||
|---|---|---|
| Gene | Primer sequence (5'-3') | (bp) |
| IS6110 | IS1 CGTGAGGGCATCGAGGTGGC | 245 |
| IS2 Bio-GCGTAGGCGTCGGTGACAAA | ||
| rpoB | Rif1 GGTCGCCGCGATCAAGGAGT | 157 |
| Rif2 Bio-TGCACGTCGCGGACCTCCA | ||
| katG | katG1 CATGAACGACGTCGAAACAG | 232 |
| katG2 Bio-CGAGGAAACTGTTGTCCCAT | ||
| inhA | inhA1 CCTCGCTGCCCAGAAAGGGA | 248 |
| inhA2 Bio-ATCCCCCGGTTTCCTCCGGT |